Heart scans reveal hidden protein buildup in rare disease
NCT ID NCT06073574
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses MRI scans to measure amyloid protein buildup in the hearts of up to 150 people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Participants are already enrolled in a larger treatment trial. The goal is to see how amyloid levels change over time, not to test a new treatment directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedale Università di Padova
Padova, 35128, Italy
-
Azienda Ospedaliero - Universitaria Careggi
Florence, 50139, Italy
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Hospital Universitario Puerta de Hierro
Majadahonda, 28222, Spain
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Richmond Pharmacology
London, SE1 1YR, United Kingdom
-
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
-
Synexus - Manchester Clinical Research Centre
Manchester, M15 6SE, United Kingdom
-
Synexus - Scotland Clinical Research Centre
Bellshill, ML4 3NJ, United Kingdom
-
Synexus - Wales
Cardiff, CF15 9SS, United Kingdom
-
Synexus Midlands Clinical Research Centre
Birmingham, B15 2SQ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.